Joseph Anthony Mara, Jr. net worth and biography

Joseph Mara, Jr. Biography and Net Worth

CFO of Vericel

Joe joined Vericel in 2021 with more than 20 years of financial, strategic and operational experience, including more than 14 years of experience in the biotech industry. Prior to joining Vericel, Joe most recently served as Vice President, Finance and Head of Investor Relations at Biogen Inc. While at Biogen, Joe held several finance leadership roles, including Vice President, Global Financial Planning and Analysis and Strategic Corporate Finance and Vice President, U.S. Finance and Operations. Joe worked across the entire Biogen organization, in roles of increasing responsibility within Finance across R&D, Corporate Finance, Corporate Strategy and Commercial operations, supporting company strategy, business development and several commercial launches. Prior to joining Biogen, Joe held finance and strategy roles in the financial services and technology industries, including at Thomson Reuters Corporation and Fidelity Investments. Joe earned a B.A. degree in Economics and International Studies from Northwestern University and an M.B.A. from the Sloan School of Management at M.I.T.

What is Joseph Anthony Mara, Jr.'s net worth?: The estimated net worth of Joseph Anthony Mara, Jr. is at least $642,402.00 as of July 12th, 2024. Mr. Mara, Jr. owns 14,436 shares of Vericel stock worth more than $642,402 as of March 29th. This net worth approximation does not reflect any other assets that Mr. Mara, Jr. may own. Learn More about Joseph Anthony Mara, Jr.'s net worth.
How do I contact Joseph Anthony Mara, Jr.?: The corporate mailing address for Mr. Mara, Jr. and other Vericel executives is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. Vericel can also be reached via phone at (617) 588-5555 and via email at ir@vcel.com. Learn More on Joseph Anthony Mara, Jr.'s contact information.
Has Joseph Anthony Mara, Jr. been buying or selling shares of Vericel?: Joseph Anthony Mara, Jr. has not been actively trading shares of Vericel during the last quarter. Most recently, Joseph Anthony Mara, Jr. sold 5,000 shares of the business's stock in a transaction on Friday, July 12th. The shares were sold at an average price of $50.00, for a transaction totalling $250,000.00. Following the completion of the sale, the chief financial officer now directly owns 14,436 shares of the company's stock, valued at $721,800. Learn More on Joseph Anthony Mara, Jr.'s trading history.
Who are Vericel's active insiders?: Vericel's insider roster includes Dominick Colangelo (President & CEO), Sean Flynn (VP), Steven Gilman (Director), Michael Halpin (COO), Jonathan Hopper (Insider), Joseph Mara, Jr. (CFO), Jonathan Siegal (Vice President & Corporate Controller), Paul Wotton (Director), and Robert Zerbe (Chairman & Director). Learn More on Vericel's active insiders.
Are insiders buying or selling shares of Vericel?: During the last year, insiders at the biotechnology company sold shares 18 times. They sold a total of 159,649 shares worth more than $7,655,811.79. The most recent insider tranaction occured on March, 13th when CEO Dominick Colangelo sold 26,592 shares worth more than $1,217,381.76. Insiders at Vericel own 5.2% of the company. Learn More about insider trades at Vericel.
Information on this page was last updated on 3/13/2025.

Joseph Anthony Mara, Jr. Insider Trading History at Vericel

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/12/2024	Sell	5,000	$50.00	$250,000.00	14,436

Joseph Anthony Mara, Jr. Buying and Selling Activity at Vericel

Vericel Company Overview

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $44.50

$44.10

$46.10

50 Day Range

MA: $53.23

$44.50

$61.80

2 Week Range

Now: $44.50

$39.12

$63.00

Volume

298,050 shs

Average Volume

377,899 shs

Market Capitalization

$2.23 billion

P/E Ratio

741.79

Dividend Yield

N/A

Beta

1.78